Bio-engineered Protein Drugs Market to Become Worth US $336.9 Billion by 2025
Albany, NY -- (SBWire) -- 03/21/2018 --Some of the prominent participants in the global bioengineered protein drugs market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Amgen, Inc., Bayer AG, Merck & Co., Inc., Dr. Reddy's Laboratories Ltd., Biocon Ltd., Eli Lilly and Company, Sanofi, Fresenius Kabi, GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Panacea Biotec, ProBioGen AG, and Reliance Life Sciences Pvt. Ltd.
Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8188
As per a report by Transparency Market Research, the global bioengineered protein drugs market will rise at a 7.4% CAGR during the period between 2017 and 2024 to become worth US$336.9 bn by 2025 from US$177.7 bn in 2016.
Depending upon the type of product, the global bioengineered protein drugs market can be classified into monoclonal antibodies, vaccines, and therapeutic protein. Of them, the therapeutic protein segment leads with maximum share because of extensive activities in the therapeutic protein engineering and recombinant DNA technology products. However, the vaccines segment is anticipated to expand at a significant CAGR from 2017 to 2025 due to rise in the development of bioengineered prophylactic and/or therapeutics vaccines.
Geographically, the key segments of the global bioengineered protein drugs market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America, of them, accounts for a dominant share in the market and going forward too is slated to retain its leading share on the back of rising instances of cancer and emergence of innovative protein therapeutics for treatment of cancer. However, the pace of growth in the North America market will be clipped to a degree on account of loss of patent of most of the blockbuster drugs, namely Rituxan, Humira, Avastin, Remicade, etc. The challenge will be overcome by the launch of new drugs in the upcoming years.
Enquiry for discount on this report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=8188
Protein engineering entails building protein through modification of amino acid. Bio engineered proteins drugs are synthesized through genetic engineering. They are used to treat injury, cancers, and also in organ transplants, among others. They are also referred to as Recombinant Protein drugs and are used for modification of immune reactions, through pathophysiological pathways at multiple levels of cells adhesion and activation.
At the forefront of driving the global bioengineered protein drug market is the increasing prevalence of infectious diseases, diabetes, cancer, etc. "Bioengineered protein drugs have proven to be more effective and have reduced or no side effects when compared with alternative therapies for cancer, diabetes, and other maladies. This has led to more healthcare physicians prescribing these drugs, thereby catalyzing growth in the market," explains the lead analyst of the TMR report.
In the years ahead too, the global market for bioengineered protein drugs is expected to expand at a good clip owing to increasing drugs in phase III of clinical trials and companies funneling money into research and development of novel bioengineered proteins.
Report Overview @ https://www.transparencymarketresearch.com/bioengineered-proteins-drugs-market.html
Serving to restrain the market, on the other hand, is the high cost of manufacturing bioengineered protein drug, having shorter shelf lifetime and development of bio similar drugs.
About Transparency Market Research
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR's syndicated reports strive to provide clients to serve their overall research requirement.
Media Relations Contact
AVP - Marketing
View this press release online at: http://rwire.com/952663